

COMPANY OVERVIEW

Aurinia Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are suffering from serious diseases with a high unmet medical need. The company is currently developing *voclosporin*, an investigational drug, for the potential treatment of lupus nephritis, focal segmental glomerulosclerosis, and Dry Eye Syndrome. The company is headquartered in Victoria, British Columbia and focuses its development efforts globally.

RECENT NEWS

Aurinia Initiates Phase 2 Clinical Trial for Voclosporin Ophthalmic Solution for the Treatment of Dry Eye Syndrome

Jul 11 2018, 4:01 PM EDT

Aurinia Initiates Clinical Trials Broadening the Development of Voclosporin

Jun 25 2018, 7:00 AM EDT

Aurinia Announces Results of Annual General Meeting

Jun 22 2018, 4:30 PM EDT

STOCK OVERVIEW

Symbol	AUPH
Exchange	Nasdaq
Market Cap	481.52m
Last Price	\$5.70
52-Week Range	\$4.41 - \$7.60

INVESTOR RELATIONS

Celia Economides
Vice President, Public Affairs
IR@auriniapharma.com

MANAGEMENT TEAM

Richard M. Glickman, L.L.D. (Hon)
CEO & Chairman of the Board

Neil Solomons, M.D.
Chief Medical Officer

Michael Martin
Chief Operating Officer

Dennis Bourgeault
Chief Financial Officer

Robert Huizinga, Ph.D., R.N., CNeph(C)
Executive Vice President, Corporate Development

Erik Eglite, D.P.M., J.D., M.B.A.
Senior Vice President, General Counsel & Chief Corporate Compliance Officer

Rashieda Gluck
Senior Vice President, Global Clinical Operations

Ron Demers
Vice President, Manufacturing and Supply Chain

Celia Economides
Vice President, Corporate & Public Affairs

Lawrence (Larry) D. Mandt
Vice President, Quality & Regulatory Affairs

Bradley J. Dickerson
General Manager, Americas & Global Commercial Lead

Simrat Randhawa, M.D., M.B.A.
Head of Global Medical Affairs

AURINIA PHARMACEUTICALS INC.

#1203-4464 Markham Street
Victoria, BC V8Z 7X8
Canada

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand

name are the property of their respective companies.